TB500 is a systemically active regenerative peptide derived from thymosin beta-4
Legal Disclaimer: The bundle (BPC-157, TB-500, MOTS-c) is sold by Protide Health for laboratory research purposes only
Except for brachytherapy APCs designated as Low Volume APCs and APC 2648, we will continue our policy and use the costs derived from CY 2024 claims data to set the final CY 2026 payment rates for brachytherapy sources
Brothers SP, Wahlestedt C
e071725e071725, www.bmj.com/content/383/bmj-2022-071725, Dangour, Alan D, et al
It is the beginning of a much larger conversation about patient access, API quality, clinical oversight, data collection, and the future of peptide compounding